Houttuynia cordata Thunb. Essential Oil Inhibits Diffuse Large B-cell lymphoma Growth

Area of Science:

• Oncology
• Pharmacology
• Natural Products

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is a prevalent non-Hodgkin lymphoma subtype with poor prognosis and limited effective treatments.
• Houttuynia cordata Thunb. is an Asian medicinal plant with known anti-inflammatory and anti-tumor properties.

Purpose of the Study:

• To investigate the therapeutic potential of Houttuynia cordata Thunb. Essential Oil (HEO) in Diffuse Large B-cell Lymphoma (DLBCL).
• To elucidate the underlying molecular mechanisms of HEO's anti-tumor activity in DLBCL.

Main Methods:

• In vitro studies on DLBCL cell lines (SUDHL-4) to assess proliferation, apoptosis, and cell cycle.
• In vivo studies using a DLBCL athymic nude mouse xenograft model to evaluate tumor growth inhibition.
• Network pharmacology analysis and phospho-specific protein microarray to identify regulated signaling pathways.
• Western blot analysis to confirm protein expression changes and compound-target docking to identify active components.

Main Results:

• HEO inhibited DLBCL cell proliferation and induced apoptosis and G0/G1 cell cycle arrest in a dose-dependent manner.
• HEO significantly suppressed DLBCL tumor growth in vivo with no observed toxicity.
• HEO was found to downregulate the PI3K/Akt signaling pathway, reducing p-PI3K and p-Akt levels.
• HEO modulated apoptosis-related proteins, decreasing Bcl-2 and increasing Bax and caspase-3 expression.
• Key HEO components like bornyl acetate, caryophyllene oxide, and terpineol showed strong binding affinity to PI3K and Akt.

Conclusions:

• HEO exhibits significant anti-tumor effects against DLBCL through the inhibition of the PI3K/Akt signaling pathway.
• HEO demonstrates potential as a novel therapeutic agent for DLBCL treatment by targeting the PI3K/Akt pathway.
• The identified active components of HEO contribute to its therapeutic efficacy in DLBCL.